MedBot seeks commercial edge with dual-use surgical robot
The company’s orthopedic robot is the first domestically developed device to be approved for both hip and knee surgeries Key Takeaways: Even with its latest product, MicroPort MedBot faces intensifying…
2252.HK
RemeGen hopes for pain relief from expanded drug uses
The innovative drug company has so far brought only two products to market, and its high sales expenses make investors worry about fallout from an anti-corruption drive Key Takeaways: RemeGen’s…
9995.HK
688331.SHG
Estrella Immunopharma nears completion of SPAC listing
The developer of T-cell cancer therapies is based in California, but says it ‘may be subject to risks’ due to its numerous China connections Key Takeaways: Estrella Immunopharma is nearing…
UPTD.US
Debt pressures cast cloud over Fosun Pharma results
The drugmaker eked out a 0.16% rise in first-half revenue, but underlying net profit slipped 26% as waning sales of Covid treatments and foreign exchange losses squeezed earnings Key Takeaways:…
2196.HK
600196.SHG
Malo Medical pitches IPO to help fill China’s dentistry gap
The provider of high-end dental services has attracted well-known investors but has yet to break even after 11 years in business, due to high sales costs Key Takeaways: Malo Medical…
New Horizon Health finds formula for profits ahead of schedule
One of China’s leading makers of early cancer screening products recorded an adjusted profit in the first half of the year as its revenue more than tripled Key Takeaways: New…
6606.HK
With healthier finances, Clover Bio shifts to flu and RSV vaccines
The Chinese vaccine developer rebounded from a deep loss into profit in the first half of the year, boosted by a one-off gain from a Covid research grant Key Takeaways:…
2197.HK
